HELX Financials

Income Statement
MetricQ4 2019Q3 2019Q2 2019Q1 2019Q4 2018
Revenue
170.7M
-19.7%
212.6M
+5.4%
201.7M
+20.9%
166.8M
+5.3%
158.4M
Cost of Revenue
144.2M
-8.5%
157.5M
-2.6%
161.8M
+7.5%
150.6M
+4.2%
144.5M
Gross Profit
26.6M
-51.7%
55.1M
+37.9%
39.9M
+145.7%
16.3M
+17.7%
13.8M
Operating Expenses
20.9M
+30.1%
16.1M
-4.7%
16.9M
+5.5%
16.0M
-7.6%
17.3M
R&D
—
—
—
—
—
SG&A
20.9M
+30.1%
16.1M
-4.7%
16.9M
+5.5%
16.0M
-7.6%
17.3M
Operating Income
5.7M
-85.5%
39.0M
+69.0%
23.1M
+8477.0%
269.0K
+107.7%
-3490000
EBITDA
5.7M
-91.5%
66.9M
+31.0%
51.1M
+77.5%
28.8M
+924.6%
-3490000
Net Income
7.9M
-74.9%
31.6M
+88.0%
16.8M
+1176.4%
1.3M
+109.6%
-13747000
EPS (Basic)
$0.06
-71.4%
$0.21
+90.9%
$0.11
+1000.0%
$0.01
+110.0%
$-0.10
EPS (Diluted)
$0.05
-76.2%
$0.21
+90.9%
$0.11
+1000.0%
$0.01
+110.0%
$-0.10
Shares (Diluted)
149.6M
+0.8%
148.4M
+0.2%
148.1M
+0.2%
147.8M
+0.6%
146.8M
Franklin Genomic Advancements ETF (HELX) — Financials